Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose Lu AA21004 5 mg versus placebo in generalized anxiety disorder
2008-001766-90Phase 3Terminated
- Sponsor
- Takeda
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Lu AA21004 5 mg QD with Placebo (2 arms). Primary endpoint: Change from baseline in HAM-A total score at 8 weeks. Started May 2008; status: terminated.
02
Drugs
vortioxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2008-001766-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001766-90.